OATD-01 for Sarcoidosis

Phase 2

Recruiting

Research Sponsored by Molecure S.A.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12-lead-ecg measured at screening and over 12 weeks of treatment or study participation - at randomization visit, at week 2 of treatment, week 4, week 8, week 12 (eot) and any fup visits. 2-week 24-h-ecg recordings at weeks 0, 4 and 8 post randomization.

Summary

This trial is testing a new drug called OATD-01 to see how well it works in treating people with active pulmonary sarcoidosis. It is a Phase 2 study, meaning it is

Who is the study for?

This trial is for men and women with active symptomatic pulmonary sarcoidosis, which means they have lung inflammation that can be seen on a special type of scan. It's open to those who haven't been treated before or have had previous treatments.

What is being tested?

The study tests OATD-01 against a placebo to see if it's effective and safe for treating pulmonary sarcoidosis. Participants won't know which one they're getting, and the effects on the body will be closely monitored.

What are the potential side effects?

While specific side effects are not listed here, common ones in trials like this may include nausea, headaches, possible allergic reactions, or other symptoms related to the lungs since it targets pulmonary conditions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12-lead-ecg measured at screening and over 12 weeks of treatment or study participation - at randomization visit, at week 2 of treatment, week 4, week 8, week 12 (eot) and any fup visits. 2-week 24-h-ecg recordings at weeks 0, 4 and 8 post randomization.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12-lead-ecg measured at screening and over 12 weeks of treatment or study participation - at randomization visit, at week 2 of treatment, week 4, week 8, week 12 (eot) and any fup visits. 2-week 24-h-ecg recordings at weeks 0, 4 and 8 post randomization.

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12-lead-ecg measured at screening and over 12 weeks of treatment or study participation - at randomization visit, at week 2 of treatment, week 4, week 8, week 12 (eot) and any fup visits. 2-week 24-h-ecg recordings at weeks 0, 4 and 8 post randomization. for reporting.